Zenas BioPharma, Inc. (ZBIO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on the stock and has a $30.00 price target.
Matthew Caufield has given his Buy rating due to a combination of factors that highlight the potential of Zenas BioPharma’s lead therapy, obexelimab. The company is advancing obexelimab, a bifunctional monoclonal antibody designed to target B cell lineage without depleting B cells, which is significant for treating autoimmune diseases. This therapy is in various stages of clinical trials for conditions like immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus, with promising expectations for upcoming trial results.
Matthew Caufield also emphasizes the differentiated approach of obexelimab compared to existing B cell therapies, which often have limitations due to incomplete B cell coverage and cytotoxicity. Obexelimab’s dual engagement of CD19 and FcγRIIb offers a reversible inhibitory effect, potentially providing a safer and more convenient treatment option. Additionally, the therapy’s subcutaneous administration could offer advantages over intravenous options, positioning Zenas BioPharma well in the market. These factors contribute to the Buy rating and a price target of $30.
Caufield covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Opthea Limited Sponsored ADR, and Mineralys Therapeutics, Inc.. According to TipRanks, Caufield has an average return of -13.1% and a 30.56% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com